Kezar Life Sciences Inc (KZR) Actualités

Form 8-K - Current report

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in...

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data...

Form 4 - Statement of changes in beneficial ownership of securities

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs...

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs...

Form 8-K - Current report

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline...

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs...